Rosetta Omics Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 4

Rosetta Omics General Information

Description

Operator of a biotechnology company intended for precision medicine in oncology. The company specializes in tumor characterization via high-resolution proteomic profiling via the combined use of mass spectrometry imaging and machine learning algorithms, and it focuses on personalized medicine by offering patients the right treatment at the right time, especially for poor-prognosis cancers like digestive cancers, enabling the healthcare industry to save patients' lives and reduce the cost of expensive, inefficient treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5 Parv. Alan Turing
  • 75013 Paris
  • France
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 5 Parv. Alan Turing
  • 75013 Paris
  • France

Rosetta Omics Timeline

202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rosetta Omics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Accelerator/Incubator 20-Oct-2025 Completed Startup
6. Grant 01-Mar-2025 Completed Startup
5. Grant 01-Nov-2024 Completed Startup
4. Early Stage VC Completed Startup
3. Accelerator/Incubator Completed Startup
2. Seed Round 18-Jul-2023 $3.3M Cancelled Startup
1. Angel (individual) $439K $439K Completed Startup
To view Rosetta Omics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Rosetta Omics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rosetta Omics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Saudi Biotechnology Accelerator Accelerator/Incubator
Bpifrance Sovereign Wealth Fund
165 Global Venture Capital Minority
Agoranov Accelerator/Incubator
To view Rosetta Omics’s complete investors history, request access »

Rosetta Omics FAQs

  • When was Rosetta Omics founded?

    Rosetta Omics was founded in 2023.

  • Where is Rosetta Omics headquartered?

    Rosetta Omics is headquartered in Paris, France.

  • What is the size of Rosetta Omics?

    Rosetta Omics has 10 total employees.

  • What industry is Rosetta Omics in?

    Rosetta Omics’s primary industry is Biotechnology.

  • Is Rosetta Omics a private or public company?

    Rosetta Omics is a Private company.

  • What is Rosetta Omics’s current revenue?

    The current revenue for Rosetta Omics is .

  • How much funding has Rosetta Omics raised over time?

    Rosetta Omics has raised $439K.

  • Who are Rosetta Omics’s investors?

    Saudi Biotechnology Accelerator, Bpifrance, 165 Global, and Agoranov have invested in Rosetta Omics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process